Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DDT | P30046 | 1/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28202370 | 0.80 | ALDH1A1 (0.35) | CYP3A4GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL28892916 | 0.70 | CYP3A4 (0.41) | CYP3A4GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL28089940 | 0.70 | CYP3A4 (0.39) | CYP3A4GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL18341916 | 0.70 | ALDH1A1 (0.36) | ALDH1A1KDM4EPMP22NPSR1RAB9A | |
| SCHEMBL12988410 | 0.68 | SYK (0.35) | CYP3A4ALDH1A1SMN1; SMN2TBXAS1 | |
| SCHEMBL311677 | 0.68 | ALDH1A1 (0.34) | ALDH1A1KDM4EPMP22NPSR1 | |
| SCHEMBL798220 | 0.68 | NAPRT (0.45) | CYP3A4GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL6502793 | 0.68 | IDO1 (0.38) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL25861866 | 0.68 | ALDH1A1 (0.44) | CYP3A4ALDH1A1TSHRTP53 | |
| SCHEMBL6237061 | 0.68 | KMT2A (0.33) | CYP3A4ALDH1A1TSHRKDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-17 | — | — | US | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CYP3A4 357/4885GABRA1 1590/4885GABRA5 1580/4885 |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CYP3A4 357/4885GABRA1 1590/4885GABRA5 1580/4885 |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | CYP3A4 255/4885GABRA1 1921/4885GABRA5 1948/4885 |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | CYP3A4 325/4885GABRA1 1750/4885GABRA5 1876/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CYP3A4 357/4885GABRA1 1590/4885GABRA5 1580/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CYP3A4 357/4885GABRA1 1590/4885GABRA5 1580/4885 |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | KLKB1, SERPINE1, SERPINB1 | CYP3A4 255/4885GABRA1 1921/4885GABRA5 1948/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CYP3A4 357/4885GABRA1 1590/4885GABRA5 1580/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | CYP3A4 325/4885GABRA1 1750/4885GABRA5 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.